4C Medical Technologies, Inc. is a medical device company developing a novel minimally invasive solution for the treatment of mitral regurgitation (MR). We are the first transcatheter MR therapy that directly addresses mitral regurgitation without replacing the native mitral valve, thus preserving the native mitral annulus and left ventricle. The device is positioned supra annular to the leaking native mitral valve to stop the leak from entering the left atrium. Its atrial only fixation ensures minimal disruption to critical cardiac structures within the left ventricle including the chordae tendineae and the left ventricular outflow tract. Our initial focus is to develop a novel therapy for mitral regurgitation (MR), and subsequently for tricuspid regurgitation (TR).